蔡木炎医生简介

蔡木炎，男，副主任医师，医学博士，博士研究生导师。
　　2005年中山大学临床医学系本科毕业后留在中山大学肿瘤防治中心病理科工作至今，累积丰富的肿瘤病理诊断经验，主要的亚专科方向为消化道肿瘤及淋巴造血系统肿瘤病理诊断。2015/10 – 2016/10，在北京生命科学研究所进行访问交流，2016/12 – 至今，在哈佛大学医学院Dana-Farber Cancer Institute做博士后。
　　

中国抗癌协会肿瘤转移专业委员会青年委员，中国肿瘤临床学会（CSCO）青年专家委员会委员，广东省抗癌协会胆道肿瘤青年委员会副主任委员。

主要从事消化道肿瘤、淋巴瘤DNA 损伤修复和肿瘤诊断标记物研究，目前以第一或通讯作者在GUT、Ebiomedicine、PLoS Genetics、Oncogene等高水平杂志发表论文30余篇，主持包括国家自然科学基金面上项目10项，广东省自然科学杰出青年基金获得者，入选广东省广东高校优秀青年人才创新计划、中山大学优秀青年教师培养重点培育计划及中山大学肿瘤防治中心临床医学科学家计划。

主要发表论著（*通讯作者；§共同第一作者）：
（1）Cai MY，Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. EZH2 Protein: a Promising Immunomarker Useful for the Detection of Hepatocellular Carcinoma in Liver Needle Biopsies. Gut. 2011; 60(7):967-976.
（2）Zhang YJ, Chen JW, He XS, Zhang HZ, Ling YH, Wen JH, Deng WH, Li P, Yun JP, Xie D, Cai MY*. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas. Ebiomedicine. 2018 [Epub ahead of print].
(3) Zhu W, Cai MY§,Tong ZT, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, Guan XY, Xie D. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut. 2012; 61(4):562-575.
(4) Zheng F, Liao YJ, Cai MY §, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012; 61(2):278-289.
(5) Tong ZT, Cai MY §，Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, Liu TH, Bian XW, Guan XY, Lin MC, Zeng MS, Zeng YX, Kung HF, Xie D. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2012; 31(5):583-594.
(6) Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF, Zeng YX, Xie D. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011; 17(1-2):12-20.
(7) Rao ZY, Cai MY§, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, Zeng YX, Kung HF, Xie D. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 2010; 31(9):1576-1583.
(8) Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL, Cai MY*. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med. 2011; 9:5.